by Anais MAX | Mar 19, 2021 | Publications
Lin28, a major translation reprogramming factor, gains access to YB-1-packaged mRNA through its cold-shock domain Abstract The RNA-binding protein Lin28 (Lin28a) is an important pluripotency factor that reprograms translation and promotes cancer progression. Although...
by Anais MAX | Jul 8, 2020 | Events
SYNSIGHT founders talk about the close relationship with the Servier team for the Pharma Day on July 8, 2020. TRANSLATION The robustness of the Synsight technology has enabled the Servier team to make possible a much wider application in several therapeutic projects...
by Anais MAX | Dec 13, 2018 | Events
SYNSIGHT presents its activity to the 1st edition of Invest4biotech at Genopole among 12 start-ups. SYNSIGHT introduces its innovative drug discovery platform, which combines artificial intelligence, experimental, and computer-aided drug design to financial sponsors....
